The Effect of COVID-19 on Type 1 Diabetes Occurrence among Children and Adolescents: A Multicenter Prospective Observational Cohort Study in Israel
Authors' conclusion
This study is the first to assess several distinct anti-SARS-CoV-2 antibodies in new-onset T1D, and our findings do not support an association between SARS-CoV-2 infection and the occurrence of T1D in children and adolescents. Since autoimmunity may emerge years after a viral infection, we recommend conducting follow-up epidemiological studies to assess whether there is a change in the incidence of T1D following the SARS-CoV-2 pandemic.
Study context
- Population
- Children and adolescents in Israel; median (IQR) age 11.4 (8.2, 13.3) years, 45% female
- Participants
- 51 vs 182
- Exposure
- Children with new-onset T1D vs controls who performed endocrine tests
- T1Dn = 51
- Controln = 182reference
- Outcome
- Seroprevalence of anti-SARS-CoV-2 antibodies (anti-S, anti-N, neutralizing) in association with T1D occurrence
Methodological detailsmulticenter, 1 : 3 ratio
- Multicenter
- 1 : 3 ratio
Main finding
As reported in the abstract
- No increase in seroprevalence of any anti-SARS-CoV-2 antibody in new-onset T1D vs control
Observational data: associations, not effects.
Further findings
Anti-S seroprevalence, without vs with DKA at T1D diagnosis (T1D group)
P = 0.035
- Anti-S seroprevalence, without vs with diabetic ketoacidosis (DKA) at T1D diagnosis (T1D group): not statistically significant after adjustment to vaccination status
Anti-N and neutralizing antibodies, DKA vs non-DKA
- Anti-N and neutralizing antibodies did not differ between DKA and non-DKA groups
Glycemic parameters
- No anti-SARS-CoV-2 antibody associated with any glycemic parameter
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →